Company Name: Paradigm Biopharmaceuticals
Announcement Date: 09/06/2016
Announcement Category: Product launch/update
Announcement Content:
PPS was safe and well tolerated in animal study, with no adverse effects
Ethics approval has been received for the Phase I clinical trial
Phase I trial to commence on 20 June 2016, expected completion on 30 August 2016
Announcement URL: http://bit.ly/1ZzLJat
About Paradigm Biopharmaceuticals:
Paradigm Biopharmaceuticals (PAR) listed on the ASX in August 2015. We focus on re-purposing pentosan polysulphate sodium (PPS) for new orthopaedic and respiratory applications. We focus on PPS because this FDA-approved drug has a long history of safety and efficacy in treating interstitial cystitis and deep vein thrombosis. Our patents cover new applications in bone marrow edema (BME) and and the allergic inflammatory response in allergic rhinitis (AR), which is commonly known as ‘Hay Fever’.
Go to Company Profile for: Paradigm Biopharmaceuticals
Announcement Contact: [email protected]
